A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Trial Details

NCT ID
NCT06907043
Phase
PHASE1 / PHASE2
Sponsor
Eikon Therapeutics
Status
RECRUITING
Cancer Type
breast
Interventions
  • EIK1004-001 (IMP1707-001)
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Lake Mary, Florida, United States|28.75888,-81.31784
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Untreated CNS metastases (measurable and/or non-measurable) not needing immediate local therapy.
  • Previously treated CNS metastases
  • Key Exclusion Criteria:
  • Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of EIK1004 (IMP1707)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find breast Trials on Trialify →